Table 6. Univariate analysis of PFS and OS in patients with uterine carcinosarcoma (significant p-values in bold).
| Variable | Progression-free survival | Overall survival | ||||
|---|---|---|---|---|---|---|
| Hazard ratio | 95%CI | p-value | Hazard ratio | 95% CI | p-value | |
| Age (> 60yr vs <60yr) |
1.20 |
0.35–4.13 |
0.771 |
1.1 |
0.53–2.28 |
0.794 |
| Family history (yes vs no) |
1.00 |
0.29–3.51 |
0.999 |
0.42 |
0.18–0.99 |
0.047 |
| Cervical smear (abnormal vs normal) |
1.45 |
0.43–4.89 |
0.548 |
2.40 |
1.03–5.60 |
0.041 |
| Stage (late vs early)* |
1.54 |
0.56–4.25 |
0.400 |
3.48 |
1.79–6.77 |
0.000 |
| Residual tumour (yes vs no) |
0.41 |
0.13–1.32 |
0.135 |
3.66 |
1.90–7.02 |
0.000 |
| Histology (homologous vs heterologous) |
0.44 |
0.10–1.88 |
0.270 |
0.71 |
0.31–1.62 |
0.418 |
| LVSI (positive vs negative) |
0.78 |
0.27–2.22 |
0.639 |
1.38 |
0.77–3.47 |
0.200 |
| Myometrial invasion > 50% (yes vs no) |
0.67 |
0.26–1.72 |
0.403 |
2.29 |
1.15–4.57 |
0.019 |
| Lower segment involvement (yes vs no) |
1.39 |
0.50–3.89 |
0.529 |
1.86 |
0.89–3.90 |
0.098 |
| Cervical involvement (yes vs no) |
1.61 |
0.63–4.13 |
0.325 |
3.38 |
1.64–6.97 |
0.001 |
| Adnexal involvement (yes vs no) |
0.663 |
0.21–2.05 |
0.475 |
3.21 |
1.56–6.63 |
0.002 |
| Necrosis (yes vs no) |
2.45 |
0.34–17.60 |
0.372 |
1.97 |
0.70–5.58 |
0.200 |
| Tumour diameter = >100mm (yes vs no) |
4.57 |
1.59–13.19 |
0.005 |
1.75 |
0.75–4.07 |
0.192 |
| Full staging (yes vs no) |
2.42 |
0.94–6.27 |
0.069 |
0.37 |
0.18–0.78 |
0.008 |
| Any other modality treatment# (yes vs no) |
0.70 |
0.27–1.80 |
0.455 |
0.48 |
0.27–0.85 |
0.012 |
*Early-stage regarded as FIGO stage I and II and late-stage as FIGO stage III and IV.
#Including chemotherapy, radiation, or hormonal therapy–as part of curative or for palliation intent.